Discover
Siliq (brodalumab) / Bausch Health, Leo Pharma, Kyowa Hakko KirinBrodalumab: Regulatory decision in China for psoriasis in H2 2020 (Kyowa Hakko Kirin Pharma) - May 1, 2020 - Q1 2020 Results
Cosentyx (secukinumab) / NovartispINPOINt: A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD) (clinicaltrials.gov) - Apr 28, 2020 - P3; N=90; Suspended; Sponsor: Novartis Pharmaceuticals; Not yet recruiting --> Suspended
Otezla (apremilast) / AmgenAmgen Inc (AMGN) Q1 2020 earnings call transcript (Amgen Press Release) - Apr 30, 2020 - "Otezla was acquired on Nov. 21, 2019 and generated $479 million of sales in the first quarter of 2020....Data from the Phase 3 study in patients with mild-to-moderate psoriasis are expected in Q2 2020....Aimovig® (erenumab-aooe) sales increased 20% driven by 46% volume growth, offset partially by lower net selling price as we expanded patient access."
GSK2831781 / GSKGSK2831781: Expiry of patents related to composition-of-matter and methods of treatment in 2036 (Immutep) - Apr 30, 2020 - Investor Presentation
Stelara (ustekinumab) / J&JStelara: Patent expiry in US in 2023 (J&J) - Apr 26, 2020 - Annual Meeting of Shareholders
Stelara (ustekinumab) / J&JComparative Study to Evaluate the Pharmacokinetics of BAT2206 vs Stelara® in Healthy Subjects (clinicaltrials.gov) - May 1, 2020 - P1; N=270; Not yet recruiting; Sponsor: Bio-Thera Solutions
PF-06700841 / PfizerDose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis (clinicaltrials.gov) - Apr 28, 2020 - P2b; N=240; Recruiting; Sponsor: Pfizer; Trial completion date: May 2020 --> Apr 2021; Trial primary completion date: May 2020 --> Apr 2021
Otezla (apremilast) / AmgenREWARD: A Study of Apremilast Use and Effectiveness in Patients With Psoriatic Arthritis in The Netherlands (clinicaltrials.gov) - Apr 29, 2020 - P=N/A; N=200; Recruiting; Sponsor: Amgen; Trial completion date: Mar 2020 --> Jun 2022; Trial primary completion date: Mar 2020 --> Jun 2022
Otezla (apremilast) / AmgenREALIZE: A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France (clinicaltrials.gov) - Apr 28, 2020 - P=N/A; N=500; Recruiting; Sponsor: Amgen; Trial primary completion date: Mar 2020 --> Mar 2021
